QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
LON:DPH

Dechra Pharmaceuticals - DPH Share Forecast, Price & News

GBX 2,546
-84.00 (-3.19%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
2,532
2,641.04
50-Day Range
2,524
3,784
52-Week Range
2,512
5,405
Volume
335,469 shs
Average Volume
332,187 shs
Market Capitalization
£2.90 billion
P/E Ratio
4,803.77
Dividend Yield
1.71%
Price Target
GBX 4,573.33

Dechra Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
79.6% Upside
GBX 4,573.33 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
£5.38 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

DPH stock logo

About Dechra Pharmaceuticals (LON:DPH) Stock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Stock News Headlines

Dechra Pharmaceuticals
2 FTSE 100 shares I’d buy as stocks fall
2 FTSE 100 growth stocks to buy right now
Dechra Pharma HY Revenue Up 15% At CER - Quick Facts
Dechra Pharmaceuticals (LSE:DPH)
See More Headlines
Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Company Calendar

Today
10/05/2022
Ex-Dividend for 11/18 Dividend
10/27/2022
Dividend Payable
11/18/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,699
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 4,573.33
High Stock Price Forecast
GBX 5,700
Low Stock Price Forecast
GBX 4,000
Forecasted Upside/Downside
+79.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£681.80 million
Cash Flow
GBX 108.27 per share
Book Value
GBX 615.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£2.90 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Ian D. Page (Age 61)
    CEO, MD & Exec. Director
    Comp: $1.26M
  • Mr. Paul Nicholas Sandland MAAT (Age 43)
    FCCA, CFO & Exec. Director
    Comp: $790k
  • Dr. Anthony Gerard Griffin (Age 59)
    MD of Dechra Veterinary Products for Europe & Exec. Director
    Comp: $601k
  • Mr. Patrick Meeus
    Group Scientific Officer
  • Ms. Katy Clough
    Group HR Director
  • Mr. Mike Eldred (Age 52)
    Pres of North America
  • Ms. Melanie Hall
    Company Sec.













DPH Stock - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DPH shares.
View DPH analyst ratings
or view top-rated stocks.

What is Dechra Pharmaceuticals' stock price forecast for 2022?

3 Wall Street research analysts have issued 1 year price objectives for Dechra Pharmaceuticals' stock. Their DPH share price forecasts range from GBX 4,000 to GBX 5,700. On average, they predict the company's share price to reach GBX 4,573.33 in the next year. This suggests a possible upside of 79.3% from the stock's current price.
View analysts price targets for DPH
or view top-rated stocks among Wall Street analysts.

How have DPH shares performed in 2022?

Dechra Pharmaceuticals' stock was trading at GBX 5,325 at the beginning of 2022. Since then, DPH shares have decreased by 52.1% and is now trading at GBX 2,551.16.
View the best growth stocks for 2022 here
.

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals announced a dividend on Monday, September 5th. Investors of record on Thursday, October 27th will be given a dividend of GBX 32.89 per share on Friday, November 18th. This represents a dividend yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 27th. This is a boost from the stock's previous dividend of GBX 12. The official announcement can be accessed at this link.
Read our dividend analysis for DPH
.

Is Dechra Pharmaceuticals a good dividend stock?

Dechra Pharmaceuticals (LON:DPH) pays an annual dividend of GBX 0.41 per share and currently has a dividend yield of 1.71%. The dividend payout ratio is 78.09%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for DPH.

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 2,551.16.

How much money does Dechra Pharmaceuticals make?

Dechra Pharmaceuticals (LON:DPH) has a market capitalization of £2.90 billion and generates £681.80 million in revenue each year.

How many employees does Dechra Pharmaceuticals have?

The company employs 1,699 workers across the globe.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The official website for the company is www.dechra.com. The company can be reached via phone at +44-1606-814730.

This page (LON:DPH) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.